argenx SE(NASDAQ : ARGX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||-1.26%||7.06||14.1%||$41.54m|
|BRBR||BellRing Brands, Inc.||-0.18%||21.71||0.0%||$20.03m|
|RVMD||Revolution Medicines, Inc.||0.11%||18.43||0.0%||$16.82m|
|BGXX||Bright Green Corp.||1.63%||1.25||0.0%||$6.91m|
|USNA||USANA Health Sciences, Inc.||-0.33%||58.35||4.2%||$3.68m|
|ANIK||Anika Therapeutics, Inc.||0.04%||23.47||9.7%||$1.99m|
|ENVB||Enveric Biosciences, Inc.||-3.40%||4.54||0.0%||$0.62m|
|NATR||Nature's Sunshine Products, Inc.||-1.60%||8.61||0.4%||$0.42m|
|FLGC||Flora Growth Corp.||-3.51%||0.88||0.0%||$0.34m|
|GHSI||Guardion Health Sciences, Inc.||7.99%||0.15||0.0%||$0.24m|
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.